Texas A&M University
Welcome,         Profile    Billing    Logout  
 44 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kerr, David J
NCT04938388: Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Terminated
4
12
US
Semaglutide Pill, Semaglutide 3 mg, Semaglutide 7 mg, Semaglutide 14 mg, Fresh organic vegetables
Sansum Diabetes Research Institute, Novo Nordisk A/S
Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
02/23
02/23
NCT05368454: Evaluation of a Digital Diabetes Self-Management Education and Support Program

Completed
N/A
100
US
Online Diabetes Self-Management Education and Support (DSMES) Program, Standard of Care
Omada Health, Inc., Abbott Diabetes Care, Evidation Health
Type 2 Diabetes
01/24
01/24
NCT05000840: Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA

Recruiting
N/A
750
US
Enrollment in existing SDRI diabetes education programs
Sansum Diabetes Research Institute, Abbott, DexCom, Inc.
Diabetes Mellitus, Type 2, Cardiovascular Diseases
07/24
12/24
Deutz, Nicolaas
PREP DOD, NCT05346302: Persistent Readiness Through Early Prediction Immunization Study

Completed
1
249
US
Pneumovax 23, Typhim VI, Saline
Texas A&M University, Philips Healthcare, US Department of Defense - Defense Threat Reduction Agency
Inflammatory Response
12/22
12/22
Smith, Stephen
COMFORT, NCT05750589: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

Not yet recruiting
3
240
US
IRX-101, Providone-Iodine
iRenix Medical, Inc.
Retinal Disease
12/26
12/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
NCT04987294: Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Terminated
2a
19
US
ALLN-346, Engineered urate oxidase, Placebo, Matching placebo capsule
Allena Pharmaceuticals
Hyperuricemia, Gout, Chronic Kidney Diseases
09/22
09/22
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
RELIEF, NCT05747430: SteRilizing Eye SoLution to ImprovE Patient ComFort

Recruiting
2
75
US
IRX-101, Providone-Iodine
iRenix Medical, Inc.
Retinal Disease
06/24
08/24
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
KT333-TL-101, NCT05225584: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Active, not recruiting
1
120
US
KT-333
Kymera Therapeutics, Inc.
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
02/25
03/25
STAR-V, NCT05024695: Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

Recruiting
N/A
975
Europe, Canada, US
MINIject™ Implant
iSTAR Medical
Glaucoma
07/27
07/29
Castorino, Kristin
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed
4
141
US
Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1
03/24
06/24
TRZ, NCT06009653: Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

Terminated
4
32
US
Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide
Washington University School of Medicine, Eli Lilly and Company, National Institute on Minority Health and Health Disparities (NIMHD)
Obesity, Metabolic Disease
05/24
05/24
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
INHALE-GDM, NCT06535789: Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Not yet recruiting
2/3
30
US
Inhaled Technosphere Insulin
Jaeb Center for Health Research, Mannkind Corporation
Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
12/24
12/24
NCT04905628: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus

Recruiting
N/A
100
US
Dexcom CGM System
DexCom, Inc.
Diabetes Mellitus
03/22
04/22
NCT05409131: Omnipod 5 System Compared to Pump Therapy

Active, not recruiting
N/A
200
Europe, US
Omnipod 5 System
Insulet Corporation
Type 1 Diabetes
09/23
01/25
SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed
N/A
343
US
Omnipod 5 Automated Glucose Control System
Insulet Corporation, Jaeb Center for Health Research
Type2 Diabetes
03/24
03/24
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

Completed
N/A
250
US
Insulin Pump with Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes
12/23
12/23
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes

Active, not recruiting
N/A
575
US
MiniMed™ 780G Insulin Pump system
Medtronic Diabetes
Type 2 Diabetes Treated with Insulin
01/25
02/25
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes

Not yet recruiting
N/A
1500
US
Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
12/25
12/25
Engelen, Marielle P
PREP DOD, NCT05346302: Persistent Readiness Through Early Prediction Immunization Study

Completed
1
249
US
Pneumovax 23, Typhim VI, Saline
Texas A&M University, Philips Healthcare, US Department of Defense - Defense Threat Reduction Agency
Inflammatory Response
12/22
12/22
Mortazavi, Bobak J
NCT06065319: Wearables and Cardiac Rehabilitation

Active, not recruiting
N/A
18
US
Wearable Sensors
Texas A&M University, Ascension Health
Cardiac Rehabilitation
06/24
10/24
Jafari, Roozbeh
NCT06065319: Wearables and Cardiac Rehabilitation

Active, not recruiting
N/A
18
US
Wearable Sensors
Texas A&M University, Ascension Health
Cardiac Rehabilitation
06/24
10/24

Download Options